Skip to content
Homepage
Clinic directory

Clinics in Washington, Utah

Every listing is checked against federal records, reviewed for evidence, and confirmed still operating. No pay-to-play. No guesswork.

  • No results found.
  • No results found.

Washington, UT

Peptide Therapy clinics in Washington

Washington has a federal and lobbying professional class with full NP practice authority, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across Georgetown, Dupont Circle, and Capitol Hill range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the GW Hospital, MedStar Georgetown, and Sibley Memorial network. The scene here skews toward concierge practices serving federal appointees, lobbyists, and diplomats. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Washington clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.

No clinics found

Try adjusting your filters or search terms

Reset all filters

Regulatory context

A note on Utah's peptide therapy rules.

Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. The FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list during 2023 and 2024, restricting 503A pharmacy sourcing. Section 503A covers traditional patient-specific compounding; Section 503B covers FDA-registered outsourcing facilities held to cGMP.

  • Utah Code Title 58 Chapter 17b (Pharmacy Practice Act)
    Governs pharmacy licensure and compounding under the Utah Division of Professional Licensing Board of Pharmacy.
  • Utah Code Title 58 Chapter 67 (Utah Medical Practice Act)
    Regulates physician prescribing and delegation.
  • Utah Code Title 58 Chapter 71 (Naturopathic Physician Practice Act)
    Licenses naturopathic physicians with prescriptive authority within a state formulary.

The Utah Division of Professional Licensing (DOPL) Board of Pharmacy inspects compounding pharmacies for USP compliance. Non-resident pharmacies shipping peptides into Utah must hold a current non-resident permit. DOPL publishes disciplinary actions.

Peptide Therapy in Washington, answered.

Washington clinics most commonly offer sermorelin and sermorelin plus ipamorelin blends for growth hormone support, both of which are FDA-approved for adult GH deficiency. Healing peptides like BPC-157 and thymosin beta-4 (TB-500) are sometimes offered, but neither is FDA-approved and both landed on the FDA's Category 2 bulk list in 2023, which restricts compounding pharmacy sourcing. CJC-1295 and tesamorelin (Egrifta) appear in some protocols; tesamorelin is FDA-approved for HIV-associated lipodystrophy only. Melanotan II, epithalon, and selank are not FDA-approved.

$450 to $700 per month for sermorelin or sermorelin plus ipamorelin blends. $600 to $1,100 per month for BPC-157 plus TB-500 protocols when available through compounding. $550 to $950 per month for peptide plus hormone optimization bundles. Expect $400 to $900 upfront for initial labs (CBC, CMP, IGF-1, hormone panel, inflammatory markers) and the intake consult. Most clinics expect a 3 to 6 month commitment with monthly or quarterly follow-ups, and injection supplies and shipping from the compounding pharmacy are usually bundled into the monthly price.

Sermorelin and tesamorelin are FDA-approved for specific indications, so those are the only peptides a DC clinic can prescribe as standard practice with full FDA backing. BPC-157, CJC-1295, ipamorelin, thymosin beta-4 (TB-500), epithalon, melanotan, and most other research peptides are not FDA-approved. The FDA's 2023-2024 Category 2 bulk substances list decision meant 503A compounding pharmacies lost legal access to many of those ingredients, so availability fluctuates. Any Washington clinic that still offers a long menu of non-approved peptides should disclose exactly where those ingredients come from.

DC grants nurse practitioners full practice authority, so NPs can evaluate, prescribe, and manage peptide protocols independently. Compounding pharmacy partnership remains required for custom peptide prescriptions, and most clinics work with a 503A pharmacy licensed in the state. The DC Board of Medicine licenses physicians and the DC Board of Pharmacy regulates compounding, with NP full practice authority. Peptides are typically administered by subcutaneous injection at home after a training session at the clinic, though some Washington offices offer in-clinic injections. Be wary of non-clinical operators selling peptides labeled as research chemicals, which is a federal red flag regardless of state law.

Verify the prescribing physician's active license through the DC medical board and confirm their NPI number through the NPPES registry. Ask which 503A compounding pharmacy supplies the peptides and whether that pharmacy is licensed in DC. Request baseline labs (CBC, CMP, IGF-1, hormone panel, inflammatory markers) before starting any growth hormone peptide, and confirm a monitoring schedule. Reputable Washington clinics in Georgetown will clearly distinguish FDA-approved peptides from off-label compounds and avoid marketing research chemicals to the public.

Filters

Rating

Treatments

Advanced Therapies 1
Chronic, Immune & Hormonal
Digestive & Respiratory
IV & Infusion
Pain & Musculoskeletal
Skin & Aesthetics
Mental Health & Neurology